Anti-Cancer Activity and Mechanism of Resveratrol Against Triple-Negative Breast Cancer

Author:

Zhang Xicai1,Wu Fengyun2,Shi Shuqiang1,Chen Peng1,Jin Mian1,Zheng Nan3

Affiliation:

1. Department of General Surgery, The People’s Hospital of Pingyang, Wenzhou, Zhejiang, 325400, China

2. Department of Hematology and Oncology, The People’s Hospital of Pingyang, Wenzhou, Zhejiang, 325400, China

3. Department of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, China

Abstract

This research analyzed the antitumor of resveratrol in triple negative breast cancer (TNBC). TNBC were divided into control group and resveratrol group. Tnbc-associated TNBC cells were stimulated by different concentrations of resveratrol, and the proliferation, apoptosis, migration of the cells were analyzed. The amount of migration was measured by Transwell method. The PI3K, Akt, and mTOR were detected. Results showed that the cell apoptosis was obvious and the invasion ability was decreased in resveratrol group, and the effect was more obvious with the increase of dosage, and there was a statistical difference between groups (P < 0.05). Resveratrol significantly decreased the expression of Akt, PI3K and mTOR, and there were statistical differences between groups (P < 0.05). In summary, resveratrol reduces cell migration, promotes cell apoptosis, inhibits cell proliferation, and its mechanism is closely related to the blocking of PI3K/Akt/mTOR.

Publisher

American Scientific Publishers

Reference34 articles.

1. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer;Bardia;New England Journal of Medicine,2019

2. Triple-negative breast cancer: A run-through of features, classification and current therapies;Manjunath;Oncology Letters,2021

3. Clinicopathological features and BRCA 1/2 status in a large prospective cohort of young women with breast cancer;Guzman-Arocho;Cancer Research,2020

4. Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer;Schmid;New England Journal of Medicine,2018

5. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy;Santonja;Oncotarget,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3